

A Perspective on Neuronal Cell Death Signaling and Neurodegeneration

Scott Brady · Gerardo Morfini

Received: 5 April 2010 / Accepted: 5 April 2010 / Published online: 18 May 2010
© Springer Science+Business Media, LLC 2010

Abstract Although neuronal cell death through apoptotic pathways represents a common feature of dysferopathies, the canonical apoptotic changes familiar from nonneuronal cells are late events. Loss of neuronal function occurs at a much early time, when synaptic-based neuronal connectivity fails. In this context, apoptotic pathways may normally serve a cleanup role, rather than a pathogenic one. Reframing the consideration of cell death in the nervous system to include the early stages of axonal degeneration provides a better understanding of the roles played by various apoptotic signaling pathways in neurodegenerative diseases. Focusing on disease-specific mechanisms that initiate the sequence that eventually leads to neuronal loss should facilitate development of therapies that preserve neuronal function and neuronal numbers.

Keyword Cell death · Apoptosis · Axonal transport · Kinesin · Dynein · Neurodegeneration · Kinases dysferopathy

Loss of neurons is typically the readout used for studies of neuropathological conditions ranging from stroke and traumatic brain injury to adult-onset neurodegenerative diseases such as Alzheimer's and Parkinson's [1]. One result is that studies of neurodegenerative disease often become descriptions of progressive neuronal cell death, and many therapeutic strategies focus on preventing cell death

[2, 3]. Unfortunately, successes in reducing or preventing neuronal cell death have not translated to effective treatments for any neurodegenerative disease [4–6]. The problem is that neurodegenerative diseases are not caused by cell death signaling pathways. Although apoptotic pathways will eventually be activated and neurons lost as the disease progresses, the clinical symptoms of neurodegenerative diseases reflect abnormalities in synaptic function and the loss of synaptic connections, rather than the loss of neurons. Conflating the shared molecular mechanisms of cell death with unique disease-specific pathogenic mechanisms of neurodegeneration may be interfering with the search for effective therapies.

Although the final common steps in cell death pathways (i.e., nuclear fragmentation, etc.) are shared between neuronal and nonneuronal cells [7, 8], the sequence of events leading to cell death in neurons may include steps not found in nonneuronal cells [9]. Neuron-specific features may involve an extended period of time, often months or years, in contrast with the rapid progression of apoptosis observed in nonneuronal cells [10]. These initial neuron-specific steps manifest as a loss of synaptic function, a process initiated at a considerable distance from the neuronal perikaryon. Complicating the situation further, components of cell death signaling pathways can play roles in neurons unrelated to cell death, such as regulating aspects of synaptic function and plasticity [11–13].

Neuron-Specific Cell Death Features

A brief consideration of some unique aspects of cell death in neurons may be useful. Both extrinsic and mitochondrial-based pathways of apoptotic cell death can be observed in neurons [8, 10, 14], depending on the

S. Brady (✉) · G. Morfini
Department of Anatomy and Cell Biology,
University of Illinois at Chicago,
808 S. Wood St., Rm 578 (M/C 512),
Chicago, IL 60612, USA
e-mail: stbrady@uic.edu

triggering stimulus. The initiators of cell death may be as diverse as failure to establish trophic relationships with a target cell, stroke, and traumatic brain injury, or neurodegenerative disease, regardless of whether they are environmental, familial, or sporadic in origin. Both apoptotic and necrotic cell deaths may be observed in neurons [8], but here, we will focus on apoptotic mechanisms. Perhaps the most obvious difference between neuronal and nonneuronal cell death is the time that it takes to complete apoptosis. The final stages of apoptotic cell death are rapid and similar in both neuronal and nonneuronal cells. However, in neurons, the early stages begin in the distal axon and presynaptic terminals and progress slowly. Months or even years may elapse between the first decrements in neuronal function and the initiation of a final apoptotic sequence.

The ways in which cell death pathways are managed in neurons differ from nonneuronal cells. The enormous size and complex functional architecture of neurons require additional layers of complexity, which are seen both in development and in pathological states. Cell death plays a critical role in sculpting the functional architecture of the nervous system during development [9, 15]. During development, programmed cell death via apoptosis assures that appropriate matches exist between neurons and their target cells. Nuclear changes are late events, and the first steps leading toward developmental neuronal death typically occur in synaptic and axonal compartments. If these steps are limited in scope and extent, synaptic and axonal changes might lead to pruning of nonproductive synaptic contacts or axonal branches [9]. Such pruning is essential for establishing sensory maps in the cortex such as those corresponding to visual space [16]. The atrophy of an axonal branch follows shutdown of synaptic function and degeneration of the presynaptic terminal, with subsequent degeneration of the distal axon. The distal axonopathy seen in early stages of neurodegenerative disease follows a similar sequence but involves a most or all of the presynaptic terminals in an affected neuron. The result is a classic dying-back neuropathy [17–19].

The sequence of events associated with loss of presynaptic function and degeneration of distal axons may be prolonged for years after the first decrement in synaptic function take place [10, 20]. This is in large part due to the size and complex morphology of neurons, which create an abundance of heterogeneous microdomains and provide new arenas for cell death-related molecular components to perform diverse functions. In some neurons, activation of kinases or caspases in a presynaptic compartment may occur a meter or more away from the nucleus. This topographic separation prevents the interaction with key downstream targets required for the progression and execution of apoptosis. Under these conditions, the critical apoptosis executioner caspase-3 [11, 12, 21] and proapop-

totic kinases like c-Jun N-terminal kinase (JNK) [22–25] may be activated in a presynaptic or postsynaptic compartment, but apoptosis does not result. A growing body of evidence indicates that some components of cell death pathways may play important roles in normal neuronal functions like the synaptic plasticity that underlies learning and memory [11–13].

However, a failure in the trophic relationships of neurons with target cells does trigger apoptosis in neurons [26–28]. This is due to the uniquely symbiotic relationship between a given neuron and the hundreds or thousands of other cells that interact with that neuron. Important interactions are associated with presynaptic and postsynaptic specializations as well as with diverse glial cells. Target cells (i.e., muscle cells, other neurons, etc.) act as a source of neurotrophins, which in turn promote survival of neurons innervating these targets. The neuron integrates these various relationships in ways that are incompletely understood. This integration is essential not only for neuronal survival but also for determining size, morphology, and various functional aspects of the neuron. Moreover, these trophic relationships are tightly tied to neuronal activity, so only productive relationships are preserved [29, 30].

Synaptic Function and Neurotrophin-Dependent Neuronal Survival

How then does a neuron progress to apoptosis either in development or in slowly progressing adult-onset neurodegenerative diseases like Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis? In both, the apoptotic process occurs as a dying-back neuropathy or distal axonopathy [31], following a characteristic sequence of events (Fig. 1). Lack of effective synaptic activity coupling neurotransmitter release to neurotrophin uptake will initiate degeneration of the presynaptic terminal [9, 17]. Loss of synaptic activity may result from reductions in critical components for neurotransmitter release in the presynaptic compartment or by failure of appropriate responses (i.e., trophic support) from target cells. In disease states, deficiencies in presynaptic components may be more common, while during development, inadequate neurotrophin supplies from non-responsive targets are more likely. For example, blockade of neurotrophin uptake during development interferes with the establishment of ocular dominance columns [32]. Similarly, both uptake and retrograde transport of neurotrophins by sensory neurons in dorsal root ganglia are needed to prevent cell death of these sensory neurons [33]. Survival of motor neurons in the spinal cord is also dependent on neuronal activity [34], and activity-dependent release of neurotrophins is critical for their biological actions [35]. Although a full review of the




Fig. 1 Stages in neuronal death as a dying-back neuropathy. **a** In the intact nervous system, neurons and targets are well matched, so activity and neurotrophic support (green arrows) are well coordinated. **b** When the activity at a given synapse is compromised, then presynaptic terminals are retracted and neurotrophin return is reduced. Changes in gene expression may occur, but the perikaryon is still intact at this stage. **c** When the number of functional synapses falls below a critical threshold, the remaining presynaptic terminals are typically shut down and retracted. Consequently, target-derived neurotrophin supplies are no longer sufficient to maintain the distal axon or to sustain neuronal viability. **d** As the distal axon atrophies, the neuronal perikaryon begins to exhibit the characteristics of classical apoptotic cell death, including pycnotic nuclei, shrinkage of cell body, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, and blebbing of the plasma membrane. The time from the earliest changes in synaptic function seen in **b** to the clear activation of apoptotic pathways in **d** may be months or years

actions of neurotrophins on synaptic plasticity [36, 37] and neuronal survival is beyond the scope of this perspective, a number of reviews have considered this issue [35, 38–41]. Regardless, both formation and maintenance of neuronal connections are closely linked to establishment of trophic relationships with target cells.

In a healthy connection, the release of neurotrophins from target cells leads to binding of neurotrophins to neuronal receptors, uptake of receptor–neurotrophin complexes into the neuron, and eventually transport of these complexes to the distant neuronal cell body. There is a close relationship between synaptic function and neurotrophin support, so neurotrophin uptake correlates with the release of neurotransmitter from the synapse [42, 43]. In turn, elevated neurotransmitter levels at the synapse stimulate release of neurotrophins from the target cell and help maintain postsynaptic structures as well as enhancing endocytosis in the presynaptic terminal [43]. For neurotrophic influences to be effective, receptors with bound ligand must be endocytosed and processed into a signaling endosome for return to the cell body [44–47]. Both local and perikaryal signalings by neurotrophin receptors are important in the maintenance of presynaptic function [29, 30]. An appropriate supply of synaptic components and neurotrophin receptors from the neuronal perikaryon to synapses and the corresponding return of signaling endosomes to the neuronal cell body are both essential processes for neuronal survival. From these observations, it is clear that the intracellular trafficking of synaptic and trophic factor components along axons plays a critical role in maintaining neuronal viability.

Axonal Transport: A Vital Supply Line for Synapses

As discussed above, synaptic activity and neurotrophic factor support represent critical cellular processes underlying the neuronal survival. An understanding of apoptotic cell death in neurons thus requires an analysis of molecular mechanisms underlying maintenance and functionality of synapses. Neurons are uniquely dependent on intracellular transport of proteins and organelles [18, 48]. Human neurons may be a meter or more in length, and even small mammalian neurons are significantly larger than non-neuronal cells. Their large size imposes certain demands on a neuron, but the polarization and complexity of neuronal morphologies create further challenges. A typical neuron has thousands of presynaptic and postsynaptic specializations. Some of these may be maintained for decades and others must be rapidly adjusted in response to local signals. The ability of synapses to respond to localized signals requires alterations in their biochemical composition. Despite periodic reports that small amounts of

protein synthesis may occur in axons (particularly growing axons), >99.9% of the proteins in axonal domains and >80% of the proteins in dendrites of mature neurons are synthesized in cell bodies and transported to sites of utilization [48]. As a result, neuronal cells face daunting logistical challenges in the coordinate synthesis, packaging, transport, and targeting of proteins to presynaptic and postsynaptic compartments. To fulfill this need, neurons must continually synthesize, transport, and deliver remarkable amounts of membrane proteins, mitochondria, cytoskeletal elements, and cytoplasmic enzymes via axonal transport mechanisms [48]. This dependence of axons and synapses on delivery of material from the cell body was recognized early by Cajal [49], although the responsible molecular motors were not discovered until the 1980s [50]. At that time, advances in digital video microscopy methods permitted real-time visualization of individual membrane-bounded organelles (MBOs) moving along single microtubules (MTs) in living cells for the first time. Application of video microscopic methods to axoplasm isolated from squid giant axons [51] produced real-time images of MBOs translocating on MTs and allowed biochemical and pharmacological characterization of fast axonal transport (FAT) [51–56]. Studies of FAT in axoplasm led to the discovery of conventional kinesin, a new class of molecular motor that defined a superfamily of proteins [55–58]. Subsequently, a cytoplasmic form of dynein [59] was identified. Although there are exceptions, most kinesins move toward the plus end of MTs and dyneins are minus end motors. The polarized distribution of MTs in the axon allows for kinesins to move MBOs from the cell body toward the cell periphery in the anterograde direction and for dyneins to move MBOs from the cell periphery toward the cell body in the retrograde direction [60, 61].

Cumulative evidence indicates that *conventional kinesin* is the main molecular motor involved in the anterograde FAT of various MBOs, including mitochondria, synaptic vesicles, and plasma membrane components. Signaling complexes (i.e., activated neurotrophin receptors) and MBOs carrying degradation products (i.e., lysosomes and multivesicular bodies) are transported retrogradely to the neuronal cell body by the multi-subunit molecular motor cytoplasmic dynein [44, 50]. However, the complexity of neuronal cell biology has also raised the issue of differential regulation of kinesins and dyneins [18, 62]. Coordination of kinesin and dynein-based FAT represents a critical component underlying synaptic function and plasticity [63]. As discussed below, an establishment of functional relationships between synaptic activity, trophic support, and axonal transport has shed important insights on the mechanisms underlying neuronal dysfunction and death in various human neurodegenerative diseases.

Axonal Transport and Dysferopathies

Adult-onset neurodegenerative diseases are among the most difficult and puzzling disorders of the nervous system. Genes associated with these diseases have been identified, and characterization of pathogenic mutations constituted major breakthroughs. However, identification of mutant genes often failed to illuminate specific pathogenic mechanisms. Biological roles for the associated gene product were often not apparent. Some diseases were associated with multiple mutations in a given gene or with mutations in different unrelated genes that all resulted in comparable pathologies. Many diseases existed in both familial and sporadic forms with indistinguishable clinical presentation. Moreover, a number of these mutant proteins were expressed in a variety of neuronal and nonneuronal cells, but only specific neuronal populations were affected. Few of the identified mutations explained either the unique vulnerability of neurons in these diseases, or why affected neurons functioned normally for decades before appearance of pathology. However, one class of neurodegeneration-associated genes was illuminating.

Recently, evidence that alteration in motor function may underlie some neuropathologies has accumulated [18, 62, 64–67], and these typically manifest as neurodegenerative diseases with the features of a dying-back neuropathy [19]. For example, loss of function mutations leading to a 50% reduction in the kinesin-1 isoform kinesin-1A (representing approximately 10% of total kinesin-1 in motor neurons) leads to a form of spastic paraplegia [68, 69], a disease involving gradual degeneration of upper motor neurons. Similarly, mutations in the cytoplasmic dynein heavy chain subunit [67, 70] or dynactin [71] result in late-onset neurodegeneration of specific neuronal populations. Although mutations in motor proteins are rare and can account for only a small fraction of neurodegenerative diseases, recent evidence indicates that FAT may be affected in a much larger fraction of neurodegenerative diseases. These alterations occurred through changes in the activity of protein kinases involved in regulation of FAT [19]. Diseases that involve compromises in FAT as an intrinsic element in their pathogenesis may be categorized as dysferopathies (from the Greek “fero” meaning to transport or carry) [19, 72].

The complexity of neuronal cell biology raised the issue of differential regulation of kinesins and dyneins [18, 62]. Altered protein phosphorylation is a common feature of neurodegenerative diseases, and several kinase and phosphatase activities have been implicated in the regulation of FAT through phosphorylation of motor protein subunits (reviewed by Morfini et al. [18, 62]).

These kinase pathways affect a variety of cellular activities, including proapoptotic pathways. However, in cases where adult-onset, slowly progressive neurodegeneration is observed, compromised FAT is likely to be a primary lesion leading to loss of neuronal connectivity and eventually to neuronal cell death. Significantly, kinases activated in some of these dysferopathies include ones with proapoptotic activity, including JNK, P38, PKC, and GSK3 β [73–79].

For example, Alzheimer's disease neurons with familial Alzheimer's disease mutations in presenilin-1 (PS1) increased activity of GSK-3 β , a regulator of kinesin-based motility in neurons [80] and a facilitator of apoptosis [73]. Analysis of FAT in PS-1 mutant neurons showed a 20% to 30% reduction in kinesin-based motility [81]. The tau filaments present in the neurofibrillary tangles characteristic of both familial and sporadic Alzheimer's brains [82] also activate GSK3 β in neurons and affect FAT [83]. Subsequently, oligomeric forms of the A β peptide associated with the amyloid characteristic of Alzheimer's were found to activate casein kinase 2, which also inhibits FAT [84] and leads to failure of synaptic transmission [85]. CK2 may be antiapoptotic in some cellular contexts [79], but in Alzheimer's, elevated CK2 activity has the paradoxical effect of shutting down FAT and hastening loss of synaptic connectivity.

Similarly, polyQ expansion diseases like Huntington's disease and spinal bulbar muscular atrophy lead to activation of the stress-activated protein kinase JNK3, which phosphorylates kinesin and reduces FAT [86, 87]. JNK family kinases are well known proapoptotic kinases, although they can also be protective in some situations [77, 78]. In neurons, this dual role may depend on different JNK isoforms, because JNK1 activity appears to be essential and constitutive, while stressors activate JNK3 (a neuron-specific JNK) and neuronal damage [88]. Significantly, JNK3 inhibits FAT, while JNK1 does not [87]. Finally, exposure to certain toxic agents like 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lead to a form of Parkinson's disease [89, 90]. MPTP and its metabolites activate caspase 3 [72, 91], but this occurs primarily in axons and terminals where dopamine transporters are enriched. When caspase 3 is activated in the axon or the terminal, it cleaves and activates PKC δ [72, 92], which in turn alters FAT and leads to failure of neurotransmission [72, 93]. Thus, activation of proapoptotic signals in neurons can lead to deficits in FAT that eventually result in loss of synaptic function and distal axonopathy.

Summary

Although neuronal cell death through apoptotic pathways represents a common feature of dysferopathies, the canon-

ical apoptotic changes familiar from nonneuronal cells are late events. Loss of neuronal function occurs at a much early time, when synaptic-based neuronal connectivity fails. In this context, apoptotic pathways may normally serve a clean-up role, rather than a pathogenic one. Reframing the consideration of cell death in the nervous system to include the early stages of axonal degeneration provides a better understanding of the roles played by various apoptotic signaling pathways in neurodegenerative diseases. Focusing on disease-specific mechanisms that initiate the sequence that eventually leads to neuronal loss should facilitate development of therapies that preserve neuronal function as well as neuronal numbers.

Acknowledgements This work was supported by grants from NINDS (NS23868) and MDA to S.B. and from the Huntington's Disease Society of America and the ALS/CVS Therapy Alliance to G.M..

References

- Okouchi M, Ekshyyan O, Maracine M, Aw TY (2007) Neuronal apoptosis in neurodegeneration. *Antioxid Redox Signal* 9:1059–1096
- Nakamura T, Lipton SA (2009) Cell death: protein misfolding and neurodegenerative diseases. *Apoptosis* 14:455–468
- Yacoubian TA, Standaert DG (2009) Targets for neuroprotection in Parkinson's disease. *Biochim Biophys Acta* 1792:676–687
- Gould TW, Buss RR, Vinsant S, Prevette D, Sun W, Knudson CM, Milligan CE, Oppenheim RW (2006) Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. *J Neurosci* 26:8774–8786
- Chiesa R, Piccardo P, Dossena S, Nowoslawski L, Roth KA, Ghetti B, Harris DA (2005) Bax deletion prevents neuronal loss but not neurological symptoms in a transgenic model of inherited prion disease. *Proc Natl Acad Sci U S A* 102:238–243
- Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL (2006) Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. *Biochem Pharmacol* 72:1197–1206
- Hengartner MO (2000) The biochemistry of apoptosis. *Nature* 407:770–776
- Bredesen DE, Rao RV, Mehlen P (2006) Cell death in the nervous system. *Nature* 443:796–802
- Raff MC, Whitmore AV, Finn JT (2002) Axonal self-destruction and neurodegeneration. *Science* 296:868–871
- Jellinger KA (2006) Challenges in neuronal apoptosis. *Curr Alzheimer Res* 3:377–391
- Bravarenko NI, Onufriev MV, Stepanichev MY, Ierusalimsky VN, Balaban PM, Gulyaeva NV (2006) Caspase-like activity is essential for long-term synaptic plasticity in the terrestrial snail *Helix*. *Eur J Neurosci* 23:129–140
- Kudryashova IV, Onufriev MV, Kudryashov IE, Gulyaeva NV (2009) Caspase-3 activity in hippocampal slices reflects changes in synaptic plasticity. *Neurosci Behav Physiol* 39:13–20
- Mattson MP, Duan W (1999) "Apoptotic" biochemical cascades in synaptic compartments: roles in adaptive plasticity and neurodegenerative disorders. *J Neurosci Res* 58:152–166
- Mattson MP, Bazan NG (2006) Apoptosis and necrosis. In: Siegel G, Albers RW, Brady ST, Price D (eds) *Basic neurochemistry*, 7th edn. Elsevier, Boston, pp 603–615

15. Burek MJ, Oppenheim RW (1996) Programmed cell death in the developing nervous system. *Brain Pathol* 6:427–446
16. LeVay S, Wiesel TN, Hubel DH (1980) The development of ocular dominance columns in normal and visually deprived monkeys. *J Comp Neurol* 191:1–51
17. Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. *Nat Rev Neurosci* 6:889–898
18. Morfini G, Pigino G, Brady ST (2005) Polyglutamine expansion diseases: failing to deliver. *Trends Molec Med* 11:64–70
19. Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH Jr, Brown H, Tiwari A, Hayward L et al (2009) Axonal transport defects in neurodegenerative diseases. *J Neurosci* 29:12776–12786
20. Zhu X, Raina AK, Perry G, Smith MA (2006) Apoptosis in Alzheimer disease: a mathematical improbability. *Curr Alzheimer Res* 3:393–396
21. Chan SL, Mattson MP (1999) Caspase and calpain substrates: roles in synaptic plasticity and cell death. *J Neurosci Res* 58:167–190
22. Ahn SM, Choe ES (2009) Alterations in GluR2 AMPA receptor phosphorylation at serine 880 following group I metabotropic glutamate receptor stimulation in the rat dorsal striatum. *J Neurosci Res* 88:992–9
23. Jong YJ, Kumar V, O'Malley KL (2009) Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. *J Biol Chem* 284:35827–38
24. Sweatt JD (2001) The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. *J Neurochem* 76:1–10
25. Yue X, Dreyfus C, Kong TA, Zhou R (2008) A subset of signal transduction pathways is required for hippocampal growth cone collapse induced by ephrin-A5. *Dev Neurobiol* 68:1269–1286
26. Hennigan A, O'Callaghan RM, Kelly AM (2007) Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. *Biochem Soc Trans* 35:424–427
27. Blochl A, Blochl R (2007) A cell-biological model of p75NTR signaling. *J Neurochem* 102:289–305
28. Nykjaer A, Willnow TE, Petersen CM (2005) p75NTR—live or let die. *Curr Opin Neurobiol* 15:49–57
29. Barker PA, Hussain NK, McPherson PS (2002) Retrograde signaling by the neurotrophins follows a well-worn trk. *Trends Neurosci* 25:379–381
30. Weible MW 2nd, Hendry IA (2004) What is the importance of multivesicular bodies in retrograde axonal transport in vivo? *J Neurobiol* 58:230–243
31. Conforti L, Adalbert R, Coleman MP (2007) Neuronal death: where does the end begin? *Trends Neurosci* 30:159–166
32. Cabelli RJ, Shelton DL, Segal RA, Shatz CJ (1997) Blockade of endogenous ligands of trkB inhibits formation of ocular dominance columns. *Neuron* 19:63–76
33. Hamburger V, Brunso-Bechtold JK, Yip JW (1981) Neuronal death in the spinal ganglia of the chick embryo and its reduction by nerve growth factor. *J Neurosci* 1:60–71
34. Pittman R, Oppenheim RW (1979) Cell death of motoneurons in the chick embryo spinal cord. IV. Evidence that a functional neuromuscular interaction is involved in the regulation of naturally occurring cell death and the stabilization of synapses. *J Comp Neurol* 187:425–446
35. Kuczewski N, Porcher C, Lessmann V, Medina I, Gaiarsa JL (2009) Activity-dependent dendritic release of BDNF and biological consequences. *Mol Neurobiol* 39:37–49
36. Schinder AF, Poo M (2000) The neurotrophin hypothesis for synaptic plasticity. *Trends Neurosci* 23:639–645
37. Thoenen H (2000) Neurotrophins and activity-dependent plasticity. *Prog Brain Res* 128:183–191
38. Carvalho AL, Caldeira MV, Santos SD, Duarte CB (2008) Role of the brain-derived neurotrophic factor at glutamatergic synapses. *Br J Pharmacol* 153(Suppl 1):S310–324
39. Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem* 72:609–642
40. Reichardt LF (2006) Neurotrophin-regulated signalling pathways. *Philos Trans R Soc Lond B Biol Sci* 361:1545–1564
41. Rose CR, Blum R, Kafitz KW, Kovalchuk Y, Konnerth A (2004) From modulator to mediator: rapid effects of BDNF on ion channels. *Bioessays* 26:1185–1194
42. Schmidt JT (2004) Activity-driven sharpening of the retinotectal projection: the search for retrograde synaptic signaling pathways. *J Neurobiol* 59:114–133
43. Lim KC, Lim ST, Federoff HJ (2003) Neurotrophin secretory pathways and synaptic plasticity. *Neurobiol Aging* 24:1135–1145
44. Cosker KE, Courchesne SL, Segal RA (2008) Action in the axon: generation and transport of signaling endosomes. *Curr Opin Neurobiol* 18:270–275
45. Howe CL, Valletta JS, Rusnak AS, Mobley WC (2001) NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. *Neuron* 32:801–814
46. Wu C, Cui B, He L, Chen L, Mobley WC (2009) The coming of age of axonal neurotrophin signaling endosomes. *J Proteomics* 72:46–55
47. Ye H, Kuruvilla R, Zweifel LS, Ginty DD (2003) Evidence in support of signaling endosome-based retrograde survival of sympathetic neurons. *Neuron* 39:57–68
48. Brady ST (1993) Axonal dynamics and regeneration. In: Gorio A (ed) *Neuroregeneration*. Raven, New York City, pp 7–36
49. Ramon y Cajal S (1928) *Degeneration and Regeneration in the Nervous System*, 1992nd edn. Oxford University Press, Oxford
50. Hirokawa N, Takemura R (2004) Molecular motors in neuronal development, intracellular transport and diseases. *Curr Opin Neurobiol* 14:564–573
51. Brady ST, Lasek RJ, Allen RD (1982) Fast axonal transport in extruded axoplasm from squid giant axon. *Science* 218:1129–1131
52. Brady ST, Lasek RJ, Allen RD, Yin H, Stossell T (1984) Gelsolin inhibition of fast axonal transport indicates a requirement for microfilaments. *Nature* 310:56–58
53. Brady ST, Lasek RJ, Allen RD (1985) Video microscopy of fast axonal transport in isolated axoplasm: A new model for study of molecular mechanisms. *Cell Motil* 5:81–101
54. Brady ST (1987) Fast axonal transport in isolated axoplasm from the squid giant axon. In: Smith RS, Bisby M (eds) *Axonal transport*, Volume 25. Alan R. Liss, New York City, pp 113–137
55. Brady ST (1985) A novel brain ATPase with properties expected for the fast axonal transport motor. *Nature* 317:73–75
56. Lasek RJ, Brady ST (1984) Adenylyl imidodiphosphate (AMPPNP), a nonhydrolyzable analogue of ATP, produces a stable intermediate in the motility cycle of fast axonal transport. *Biol Bull* 167:503
57. Lasek RJ, Brady ST (1985) Attachment of transported vesicles to microtubules in axoplasm is facilitated by AMP-PNP. *Nature* 316:645–647
58. Vale RD, Reese TS, Sheetz MP (1985) Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. *Cell* 42:39–50
59. Shpetner HS, Paschal BM, Vallee RB (1988) Characterization of the microtubule-activated ATPase of brain cytoplasmic dynein (MAPIC). *J Cell Biol* 107:1001–1009
60. Hirokawa N (1998) Kinesin and dynein superfamily proteins and the mechanism of organelle transport. *Science* 279:519–526
61. Vale RD (2003) The molecular motor toolbox for intracellular transport. *Cell* 112:467–480

62. Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST (2002) Fast axonal transport misregulation and Alzheimer's disease. *Neuro-molecular Med* 2:89–99
63. Puthanveetil SV, Monje FJ, Miniaci MC, Choi YB, Karl KA, Khandros E, Gawinowicz MA, Sheetz MP, Kandel ER (2008) A new component in synaptic plasticity: upregulation of kinesin in the neurons of the gill-withdrawal reflex. *Cell* 135:960–973
64. Hirokawa N, Takemura R (2003) Biochemical and molecular characterization of diseases linked to motor proteins. *Trends Biochem Sci* 28:558–565
65. Holzbaur EL (2004) Motor neurons rely on motor proteins. *Trends Cell Biol* 14:233–240
66. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ et al (2003) Mutant dynactin in motor neuron disease. *Nat Genet* 33:455–456
67. Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S, Lalli G, Witherden AS, Hummerich H, Nicholson S et al (2003) Mutations in dynein link motor neuron degeneration to defects in retrograde transport. *Science* 300:808–812
68. Fichera M, Lo Giudice M, Falco M, Sturnio M, Amata S, Calabrese O, Bigoni S, Calzolari E, Neri M (2004) Evidence of kinesin heavy chain (KIF5A) involvement in pure hereditary spastic paraplegia. *Neurology* 63:1108–1110
69. Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA et al (2002) A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). *Am J Hum Genet* 71:1189–1194
70. Chen XJ, Levedakou EN, Millen KJ, Wollmann RL, Soliven B, Popko B (2007) Proprioceptive sensory neuropathy in mice with a mutation in the cytoplasmic dynein heavy chain 1 gene. *J Neurosci* 27:14515–14524
71. Puls I, Oh SJ, Sumner CJ, Wallace KE, Floeter MK, Mann EA, Kennedy WR, Wendelschafer-Crabb G, Vortmeyer A, Powers R et al (2005) Distal spinal and bulbar muscular atrophy caused by dynactin mutation. *Ann Neurol* 57:687–694
72. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinas RR, Brady ST (2007) 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. *Proc Natl Acad Sci U S A* 104:2442–2447
73. Li X, Bijur GN, Jope RS (2002) Glycogen synthase kinase-3 β , mood stabilizers, and neuroprotection. *Bipolar Disord* 4:137–144
74. Lin A (2003) Activation of the JNK signaling pathway: breaking the brake on apoptosis. *Bioessays* 25:17–24
75. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. *Biochem J* 369:1–15
76. Weishaupt JH, Neusch C, Bahr M (2003) Cyclin-dependent kinase 5 (CDK5) and neuronal cell death. *Cell Tissue Res* 312:1–8
77. Liu J, Lin A (2005) Role of JNK activation in apoptosis: a double-edged sword. *Cell Res* 15:36–42
78. Bode AM, Dong Z (2007) The functional contrariety of JNK. *Mol Carcinog* 46:591–598
79. Duncan JS, Litchfield DW (2008) Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. *Biochim Biophys Acta* 1784:33–47
80. Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. *EMBO J* 23:281–293
81. Pigino G, Morfini G, Mattson MP, Brady ST, Busciglio J (2003) Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. *J Neurosci* 23:4499–4508
82. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer's disease. *Biochim Biophys Acta* 1739:216–223
83. Lapointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST (2009) The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. *J Neurosci Res* 87:440–451
84. Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, Jungbauer L, LaDu M, Busciglio J, Brady ST (2009) Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. *Proc Natl Acad Sci U S A* 106:5907–5912
85. Moreno HH, Yu E, Pigino G, Hernandez I, Kim N, Moreira JE, Sugimori M, Llinas R (2009) Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. *Proc Natl Acad Sci U S A* 106:5901–5906
86. Morfini G, Pigino G, Szebenyi G, You Y, Pollema S, Brady ST (2006) JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. *Nat Neurosci* 9:907–916
87. Morfini GA, You YM, Pollema SL, Kaminska A, Liu K, Yoshioka K, Bjorkblom B, Coffey ET, Bagnato C, Han D et al (2009) Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. *Nat Neurosci* 12:864–871
88. Coffey ET, Smiciene G, Hongisto V, Cao J, Brecht S, Herdegen T, Courtney MJ (2002) c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. *J Neurosci* 22:4335–4345
89. Bove J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's disease. *NeuroRx* 2:484–494
90. Speciale SG (2002) MPTP: insights into parkinsonian neurodegeneration. *Neurotoxicol Teratol* 24:607–620
91. Turmel H, Hartmann A, Parain K, Douhou A, Srinivasan A, Agid Y, Hirsch EC (2001) Caspase-3 activation in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated mice. *Mov Disord* 16:185–189
92. Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, Kanthasamy AG (2003) Caspase-3 dependent proteolytic activation of protein kinase C δ mediates and regulates 1-methyl-4-phenylpyridinium (MPP⁺)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. *Eur J Neurosci* 18:1387–1401
93. Serulle Y, Morfini G, Pigino G, Moreira JE, Sugimori M, Brady ST, Llinas RR (2007) 1-Methyl-4-phenylpyridinium induces synaptic dysfunction through a pathway involving caspase and PKC δ enzymatic activities. *Proc Natl Acad Sci U S A* 104:2437–2441